Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the ...
New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...
“How I Knew I Had Ovarian Cancer”: A Patient’s Story Reveals an Unexpected Benefit of Daily Exercise
A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...
AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...
ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...
Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.
As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback